MOH — authorised 5 May 2017
- Marketing authorisation holder: MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA INC
- Status: likely_approved
MOH authorised Radicava on 5 May 2017
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 5 May 2017.
MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA INC holds the UAE marketing authorisation.